Biologics are changing the way we treat disease, affecting where companies invest and, most importantly, impacting patients’ lives. Last year, nearly half of the 37 new drugs approved by FDA’s Center for Drug Evaluation and Research (CDER) were biologics. Its partner agency — the agency’s Center for Biologics Evaluation and Research (CBER)—approved a dozen additional…